Cargando…

Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines

PARP inhibitors (PARPi), such as Olaparib, have shown promising results in high-grade serous (HGS) epithelial ovarian cancer (EOC) treatment. PARPi sensitivity has been mainly associated with homologous recombination (HR) deficiency, but clinical trials have shown that predicting actual patient resp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fleury, Hubert, Carmona, Euridice, Morin, Vincent G., Meunier, Liliane, Masson, Jean-Yves, Tonin, Patricia N., Provencher, Diane, Mes-Masson, Anne-Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522225/ https://www.ncbi.nlm.nih.gov/pubmed/27374179 http://dx.doi.org/10.18632/oncotarget.10308

Ejemplares similares

Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease
por: Fleury, Hubert, et al.
Publicado: (2015)

RAN Nucleo-Cytoplasmic Transport and Mitotic Spindle Assembly Partners XPO7 and TPX2 Are New Prognostic Biomarkers in Serous Epithelial Ovarian Cancer
por: Cáceres-Gorriti, Katia Y., et al.
Publicado: (2014)

Subtype Specific Elevated Expression of Hyaluronidase-1 (HYAL-1) in Epithelial Ovarian Cancer
por: Yoffou, Paule Héléna, et al.
Publicado: (2011)

Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence
por: Fleury, Hubert, et al.
Publicado: (2019)

Ran GTPase: A Key Player in Tumor Progression and Metastasis
por: Boudhraa, Zied, et al.
Publicado: (2020)

Carboplatin response in preclinical models for ovarian cancer: comparison of 2D monolayers, spheroids, ex vivo tumors and in vivo models
por: Brodeur, Melica Nourmoussavi, et al.
Publicado: (2021)

Low expression of the X-linked ribosomal protein S4 in human serous epithelial ovarian cancer is associated with a poor prognosis
por: Tsofack, Serges P, et al.
Publicado: (2013)

Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome
por: Gambaro, Karen, et al.
Publicado: (2015)

Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer
por: Sauriol, Alexandre, et al.
Publicado: (2023)

Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors
por: Marques, Maud, et al.
Publicado: (2015)

Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors
por: Ouellet, Véronique, et al.
Publicado: (2008)

Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems
por: Patra, Bishnubrata, et al.
Publicado: (2020)

NR1D1 regulation by Ran GTPase via miR4472 identifies an essential vulnerability linked to aneuploidy in ovarian cancer
por: Boudhraa, Zied, et al.
Publicado: (2021)

Ran promotes membrane targeting and stabilization of RhoA to orchestrate ovarian cancer cell invasion
por: Zaoui, Kossay, et al.
Publicado: (2019)

Chromosome 3 Anomalies Investigated by Genome Wide SNP Analysis of Benign, Low Malignant Potential and Low Grade Ovarian Serous Tumours
por: Birch, Ashley H., et al.
Publicado: (2011)

A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis
por: Communal, Laudine, et al.
Publicado: (2021)

Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer
por: Létourneau, Isabelle J, et al.
Publicado: (2012)

BMP-2 signaling in ovarian cancer and its association with poor prognosis
por: Le Page, Cécile, et al.
Publicado: (2009)

Modeling the Diversity of Epithelial Ovarian Cancer through Ten Novel Well Characterized Cell Lines Covering Multiple Subtypes of the Disease
por: Sauriol, Alexandre, et al.
Publicado: (2020)

Pre-operative Circulating Plasma Gelsolin Predicts Residual Disease and Detects Early Stage Ovarian Cancer
por: Asare-Werehene, Meshach, et al.
Publicado: (2019)

PRP4K is a HER2-regulated modifier of taxane sensitivity
por: Corkery, Dale P, et al.
Publicado: (2015)

A COEUR cohort study of SATB2 expression and its prognostic value in ovarian endometrioid carcinoma
por: Le Page, Cécile, et al.
Publicado: (2019)

High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer
por: Bareche, Yacine, et al.
Publicado: (2021)

Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines
por: Amuzu, Setor, et al.
Publicado: (2021)

Characterization of three new serous epithelial ovarian cancer cell lines
por: Ouellet, Véronique, et al.
Publicado: (2008)

Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers
por: Labrie, Marilyne, et al.
Publicado: (2017)

The Genomic Landscape of TP53 and p53 Annotated High Grade Ovarian Serous Carcinomas from a Defined Founder Population Associated with Patient Outcome
por: Wojnarowicz, Paulina M., et al.
Publicado: (2012)

An essential role for Ran GTPase in epithelial ovarian cancer cell survival
por: Barrès, Véronique, et al.
Publicado: (2010)

The human organic cation transporter OCT1 mediates high affinity uptake of the anticancer drug daunorubicin
por: Andreev, Emil, et al.
Publicado: (2016)

Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases
por: Tabariès, Sébastien, et al.
Publicado: (2015)

STAT1‐associated intratumoural T(H)1 immunity predicts chemotherapy resistance in high‐grade serous ovarian cancer
por: Au, Katrina K, et al.
Publicado: (2016)

Influence of monolayer, spheroid, and tumor growth conditions on chromosome 3 gene expression in tumorigenic epithelial ovarian cancer cell lines
por: Cody, Neal AL, et al.
Publicado: (2008)

Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent
por: Cavallone, Luca, et al.
Publicado: (2008)

Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression
por: Cheasley, Dane, et al.
Publicado: (2022)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers
por: Tinker, Anna V., et al.
Publicado: (2022)

Contribution of the PALB2 c.2323C>T [p.Q775X] Founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent
por: Tischkowitz, Marc, et al.
Publicado: (2013)

Germline TP53 mutational spectrum in French Canadians with breast cancer
por: Arcand, Suzanna L, et al.
Publicado: (2015)

A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population
por: Belanger, Moria H, et al.
Publicado: (2015)

Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer
por: Raspaglio, Giuseppina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7udn33oaq3vr77i1al778lktlu